arrow
T

Thomas M. Zollner

Bayer AG
H指数:37
被引数:5,267

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A systems-based approach to uterine fibroids identifies differential splicing associated with abnormal uterine bleeding

基于系统的子宫肌瘤研究方法识别与异常子宫出血相关的差异剪接

2025-07-310
OAAI
Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839

IRAK4抑制剂BAY1834845 (Zabedosertib) 和BAY1830839的发现

2024-01-177
OAAI
Neuropeptide S receptor 1 is a nonhormonal treatment target in endometriosis
2021-08-2527
OA
Preclinical models of endometriosis and interstitial cystitis/bladder pain syndrome: an Innovative Medicines Initiative-PainCare initiative to improve their value for translational research in pelvic pain
PAIN
IF5.5
2021-03-0316
OAAI
Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women
2020-09-229
OAAI
Amine oxidase 3 is a novel pro-inflammatory marker of oxidative stress in peritoneal endometriosis lesions (vol 10, 1495, 2020)
2020-03-241
OAAI
Amine oxidase 3 is a novel pro-inflammatory marker of oxidative stress in peritoneal endometriosis lesions
2020-01-3017
OAAI
Discovery and Characterization of the Potent and Selective P2X4 Inhibitor N-[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and Structure-Guided Amelioration of Its CYP3A4 Induction Profile
2019-11-2041
PREAI
Identification of a Benzimidazolecarboxylic Acid Derivative (BAY 1316957) as a Potent and Selective Human Prostaglandin E2 Receptor Subtype 4 (hEP4-R) Antagonist for the Treatment of Endometriosis
2019-02-0118
PREAI
Preclinical evaluation of a novel interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor in combination with PI3K inhibitor copanlisib or BTK inhibitors in ABC-DLBCL
2018-07-011
PRE